ADAP:NSD-Adaptimmune Therapeutics plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 5.27

Change

+0.05 (+0.86)%

Market Cap

USD 0.82B

Volume

0.64M

Avg Analyst Target

USD 7.57 (+43.67%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. to develop and commercialize allogeneic cell therapies to treat various oncology indications. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-1.23 (-0.37%)

USD135.16B 39.56 31.39
BNTX BioNTech SE

+1.76 (+0.67%)

USD60.07B 13.82 10.18
REGN Regeneron Pharmaceuticals Inc

+8.63 (+1.59%)

USD58.13B 9.81 7.57
VRTX Vertex Pharmaceuticals Incorpo..

+4.61 (+2.55%)

USD47.16B 23.84 15.87
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

+15.19 (+4.21%)

USD33.67B N/A N/A
SGEN Seagen Inc

+2.22 (+1.29%)

USD31.29B 53.66 40.74
GMAB Genmab A/S

+0.80 (+1.80%)

USD29.05B 74.96 8.12
ALNY Alnylam Pharmaceuticals Inc

+2.69 (+1.32%)

USD24.23B N/A N/A
RPRX Royalty Pharma plc

+0.68 (+1.84%)

USD23.31B 29.98 12.47

ETFs Containing ADAP

Symbol Name Weight Mer Price(Change) Market Cap
MOON Direxion Moonshot Innovat.. 0.00 % 0.65 %

+0.62 (+1.90%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.23% 64% D 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.23% 64% D 36% F
Trailing 12 Months  
Capital Gain -2.23% 54% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.23% 54% F 24% F
Trailing 5 Years  
Capital Gain -0.94% 52% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.94% 52% F 26% F
Average Annual (5 Year Horizon)  
Capital Gain 58.49% 79% C+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 58.49% 79% C+ 87% B+
Risk Return Profile  
Volatility (Standard Deviation) 152.89% 17% F 10% F
Risk Adjusted Return 38.26% 65% D 54% F
Market Capitalization 0.82B 70% C- 62% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.91 58% F 46% F
Price / Cash Flow Ratio -15.22 70% C- 77% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -43.43% 64% D 31% F
Return on Invested Capital -57.46% 43% F 15% F
Return on Assets -20.87% 60% D- 18% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.83 86% B 80% B-
Short Percent 2.63% 72% C- 52% F
Beta 2.12 16% F 11% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector